SEC Form 4 · accession 0001181431-15-003650
Orexigen Therapeutics, Inc. · OREXQ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark D Booth
Officer — Chief Commercial Officer
Period of report
Feb 26, 2015
Accepted (ET)
Mar 2, 2015 · 5:34 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001382911
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 26, 2015 | M | 50,000 | $1.66 | A | 53,810 | D | |
| Common StockF3 | Feb 26, 2015 | S | 50,000 | $5.684 | D | 3,810 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5,F4 | $1.66 | Feb 26, 2015 | M | 50,000 | D | — | Jul 24, 2021 | Common Stock | 50,000 | 563,924 | D |
Explanation of responses
- F1The exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2014.
- F2The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2014.
- F3Weighted average from 16 transactions with prices ranging from $5.66 to $5.85. Upon request by the Commission staff, the Issuer or a security holder of the Issuer, the Reporting Person will undertake to provide full information regarding the number of shares purchased at each separate price.
- F41/48th of the total number of shares of stock subject to the option (rounded down to the next whole number of shares) (which option is referred to in this Form 4 as the "Replacement Grant") shall vest on the same day of each one-month period of the Reporting Person's service as an employee, director or consultant following July 25, 2011, so that all of the shares of the stock subject to the option shall be vested on July 25, 2015, subject to the Reporting Person's continued service relationship (whether as an employee, director or consultant) with the Company or any parent or subsidiary on each such date.
- F5N/A